v3.25.3
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Cash flow from operating activities:    
Net income $ 1,341.8 $ 1,365.5
Adjustments to reconcile net income to net cash flow from operating activities:    
Depreciation and amortization 579.7 489.2
Impairment of intangible assets 3.5 20.2
Excess and obsolescence charges related to inventory 13.9 68.7
Amortization of acquired inventory step-up 165.4 185.1
Share-based compensation 231.2 216.1
Contingent consideration 28.4 23.8
Deferred income taxes 194.7 (99.7)
(Gain) loss on strategic investments 33.7 22.7
Gain on sale of priority review voucher, net 0.0 (88.6)
Other 49.3 95.1
Changes in operating assets and liabilities, net of effects of business acquired:    
Inventory (35.3) (207.4)
Accrued expense and other current liabilities (32.7) (84.2)
Income tax assets and liabilities (764.1) 62.1
Other changes in operating assets and liabilities, net (179.9) (65.7)
Net cash flow provided by (used in) operating activities 1,692.7 2,114.6
Cash flow from investing activities:    
Purchases of property, plant and equipment (109.9) (114.4)
Purchases of marketable securities (91.0) 0.0
Acquisition of HI-Bio, net of cash acquired 0.0 (1,074.8)
Proceeds from sale of equity interest in Samsung Bioepis 0.0 406.8
Proceeds from sale of priority review voucher 0.0 88.6
Acquisitions of intangible assets (15.3) (179.1)
Proceeds from sales of strategic investments 56.6 96.7
Other 20.2 (4.4)
Net cash flow provided by (used in) investing activities (139.4) (780.6)
Cash flow from financing activities:    
Payments related to issuance of stock for share-based compensation arrangements, net (13.0) (34.8)
Proceeds from borrowings 1,733.1 0.0
Repayments of borrowings (1,750.0) (650.0)
Cash paid for contingent consideration (141.3) 0.0
Other 6.3 (6.6)
Net cash flow provided by (used in) financing activities (164.9) (691.4)
Net increase (decrease) in cash and cash equivalents 1,388.4 642.6
Effect of exchange rate changes on cash and cash equivalents 99.4 6.7
Cash and cash equivalents, beginning of the period 2,375.0 1,049.9
Cash and cash equivalents, end of the period 3,862.8 1,699.2
Nonrelated Party    
Changes in operating assets and liabilities, net of effects of business acquired:    
Accounts receivable 74.9 127.6
Related Party    
Changes in operating assets and liabilities, net of effects of business acquired:    
Accounts receivable $ (11.8) $ (15.9)